Automation & Robotics

#Academic #AI / data analytics / healthtech / informatics #Analysis #Animal models #Assay development optimisation & technology #Automation / robotics #Biochemistry #Biomarkers #Business #Cell culture #Cell therapy #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Gene editing #Gene therapy #Genetics / genomes #Genetics / genomics #Genomics #High throughput screening #Lead discovery #Oncology #Orphan drugs #PCR #Precision medicine #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Sequencing #Stem cells #System biology #Systems biology #Target validation #Translational #Translational chemistry

The Post Genomic Era: What Does It All Mean?

The Post Genomic Era: What Does It All Mean? By Dr Chris Torrance Information may no longer be a bottleneck to understanding and tackling complex genetic diseases such as cancer. For those who cut their research teeth not so very long ago, before PCR was thought of by Kary Mullis,… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Assay development & optimisation #Assay development optimisation & technology #Automation / robotics #Biochemistry #Business #Cellular assays #Chemical engineering #Chemistry #Clinical specialities #Drug development #Drug discovery #Drug targets #Enabling technologies #Flow Cytometry #Genetics / genomes #Genetics / genomics #Genomics #High Content Screening #High throughput screening #Immunology #Lead discovery #Lead optimisation #Mass spectrometry / NMR #Oncology #PCR #Preclinical #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Sequencing #Stem cells #System biology #Systems biology #Target validation #Therapeutics #Toxicology #Translational #Translational chemistry #Urinary

Epigenetics: An Emerging Target Class for Drug Screening

Epigenetics: An Emerging Target Class for Drug Screening By Dr John Comley Heightened awareness of the potential importance of epigenetic targets in many disease areas, and growing vendor interest in developing new assays to screen DNA methylation and histone modifications encouraged HTStec to undertake market research in this area in… Read More

#Archive

#Automation / robotics #Biologics / Biotechnology #Business #Cell therapy #Cellular & Molecular biology #Clinical trials #Drug development #Drug discovery #Drug targets #Gene therapy #Genetics / genomes #Immunology #Lead discovery #Oncology #Pharmokinetics #Regulatory #RNA

Balancing A Biologics Pipeline Portfolio

Balancing A Biologics Pipeline Portfolio By Dr Herren Wu Research into groundbreaking biologic therapies has significantly shifted the diagnosis and treatment paradigms for many disease categories, particularly in oncology, autoimmune, inflammation and neurology. Discovering and developing an innovative, first-in-class biologic has the potential to offer patients significant benefits as well… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Automation / robotics #Biomarkers #Business #Cell / tissue culture #Cell culture #Cellular assays #Chemical engineering #Clinical specialities #Drug development #Drug discovery #Drug targets #Enabling technologies #Genomics #High Content Screening #High throughput screening #Lead discovery #RNA #Screening #Stem cells #Target validation

High Throughput Screening Systems: Impact of Reliability on Downtime

High Throughput Screening Systems: Impact of Reliability on Downtime and Drug Discovery By Dr John Comley This article reports the results of a survey on the reliability of automated HTS assay systems and the effect of reliability on output. Evidence supporting the view that high throughput screening (HTS) systems have… Read More

#Archive

#Academic #Analysis #Analytical chemistry #Animal models #Assay development optimisation & technology #Automation / robotics #Biomarkers #Business #Cell therapy #Cellular assays #Chemical engineering #Chemistry #Clinical trials #Drug development #Drug discovery #Enabling technologies #Gene therapy #Genetics / genomes #Genetics / genomics #Genomics #High Content Screening #High throughput screening #Imaging #Immunology #Mass spectrometry / NMR #Molecular medicine #Oncology #Pharmacology #Precision medicine #Preclinical #Protein chemistry / Proteomics #Regulatory #RNA #Screening #System biology #Target validation #Translational #Translational chemistry

Protein Biomarker Immunoassays: Opportunities and Challenges

Protein Biomarker Immunoassays: Opportunities and Challenges By Dr M. Walid Qoronfleh and Dr Klaus Lindpaintner With the biopharma industry under heavy pressure, transforming the scientific interchange between the laboratory and the clinic is exceedingly critical. Realising the costly toll of drug attrition in late-stage development, many companies are turning to… Read More

#Archive

#Academic #Analysis #Assay development optimisation & technology #Automation / robotics #Biochemistry #Biomarkers #Business #Cell culture #Cellular & Molecular biology #Cellular assays #Drug development #Drug discovery #Drug targets #Enabling technologies #Genetics / genomes #High Content Screening #High throughput screening #Imaging #Immunology #Lead discovery #Lead optimisation #PCR #Pharmacology #Pharmokinetics #Screening #Stem cells #System biology #Systems biology #Toxicology

Moving Forward With Label-Free Technology

Moving Forward With Label-Free Technology By Dr Jennifer Hartigan, Cindy Liu and William Downey Label-free technology is gaining acceptance and opening doors for new drug discovery. Relatively new in the well-established world of high throughput screening (HTS), label-free technology provides opportunities for probing biomolecular interactions without spatial-interference, auto-fluorescent or quenching… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Automation / robotics #Biochemistry #Business #Chemical engineering #Chemistry #Clinical specialities #Computational chemistry #Drug development #Drug discovery #Genomics #Lead discovery #Medicinal chemistry #Microfluidics #RNA

Assessing the Value of R&D Partnerships

Assessing the Value of R&D Partnerships By Dr David A Pardoe, Dr Jackie Hunter MBE, Dr Robert M Cooke and Dr Paul Barrett In response to the need to increase the return on investment in R&D, many large Pharma companies are shifting from an internal fixed resource model to more… Read More

#Archive

#Analysis #Assay development & optimisation #Assay development optimisation & technology #Automation / robotics #Biochemistry #Cell / tissue culture #Cell culture #Cellular & Molecular biology #Cellular assays #Chemistry #Clinical specialities #Drug development #Drug discovery #Drug targets #Enabling technologies #Genetics / genomes #High Content Screening #High throughput screening #Imaging #Lead discovery #Lead optimisation #Mass spectrometry / NMR #Medicinal chemistry #Pathology #PCR #Pharmacology #Pharmokinetics #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Stem cells #System biology #Systems biology #Toxicology

Current Trends in Label-Free Drug Discovery Technologies

Current Trends in Label-Free Drug Discovery Technologies By Philip Rawlins Drug Discovery Label-free technologies have been used throughout drug discovery for the detection and characterisation of molecular interactions. The implementation of automated systems, increased sensitivity and the development of new technologies have recently broadened the use of label-free methods from… Read More

#Archive

#ADME / Tox #AI / data analytics / healthtech / informatics #Analysis #Assay development & optimisation #Assay development optimisation & technology #Automation / robotics #Biomarkers #Business #Cellular assays #Clinical trials #Drug development #Drug discovery #Genomics #High Content Screening #High throughput screening #Lead discovery #Mass spectrometry / NMR #Metabolomics #Molecular medicine #Precision medicine #Preclinical #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Sequencing #System biology #Systems biology #Therapeutics #Toxicology

Mass Spectrometry in Drug Discovery and Development

Mass Spectrometry is a mature technology predicated on a premise demonstrated almost a century ago. It is widely used in most scientific disciplines involving basic research or industrial endeavours, that require accurate and precise measurement of elemental and molecular components. More recently it has become one of the foundation technologies… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Assay development & optimisation #Assay development optimisation & technology #Automation / robotics #Business #Cell culture #Cellular & Molecular biology #Cellular assays #Drug development #Drug discovery #Enabling technologies #High Content Screening #High throughput screening #Lead discovery #Lead optimisation #PCR #Screening #Sequencing #Stem cells

Bulk Reagent Dispensers: Ubiquitous liquid handling tool for microplate filling

Bulk Reagent Dispensers: Ubiquitous liquid handling tool for microplate filling By Dr John Comley The initial success of the bulk reagent dispenser (BRD) as an automated liquidhandling product can be attributed to its simplicity and low cost. Its current role as an essential dispensing tool in those labs requiring microplate… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Assay development & optimisation #Assay development optimisation & technology #Automation / robotics #Business #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Clinical trials #Combinatorial chemistry #Computational chemistry #Drug development #Drug discovery #Drug targets #High Content Screening #High throughput screening #Imaging #Lead discovery #Lead optimisation #Microfluidics #Pharmacology #Regulatory #RNA #Screening #Stem cells #System biology #Systems biology #Target validation #Toxicology

Overcoming Bottlenecks in Drug Discovery

Overcoming Bottlenecks in Drug Discovery By Dr Trevor Perrior Developing a new drug is an expensive and time-consuming process. The best current estimate puts the cost of developing a single new drug at close to $1 billion. After a drug candidate has entered the clinical trial process it takes, on… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Assay development optimisation & technology #Automation / robotics #Biomarkers #Business #Cell culture #Cellular assays #Chemical engineering #Clinical specialities #Drug development #Drug discovery #Drug targets #High Content Screening #Lead discovery #Preclinical #RNA #Screening #Therapeutics #Toxicology

Is the Pharmaceutical Industry Open For Innovation?

Is the Pharmaceutical Industry Open For Innovation? By Dr Jackie Hunter CBE Open innovation is the hot topic in many industries and this approach has the potential to make a radical difference to the costs of drug discovery and development in the pharmaceutical industry. But there are also barriers to… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Automation / robotics #Biomarkers #Cell culture #Cell therapy #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Clinical trials #Drug development #Drug discovery #Drug targets #Flow Cytometry #Gene therapy #Genetics / genomes #Genetics / genomics #Genomics #High Content Screening #High throughput screening #Imaging #Immunology #Lead discovery #Lead optimisation #Medicinal chemistry #Microbiology #Molecular medicine #Oncology #Orphan drugs #Pathology #PCR #Pharmacology #Preclinical #Protein chemistry / Proteomics #RNA #Screening #Stem cells #System biology #Systems biology #Therapeutics #Toxicology #Translational #Translational chemistry

High Throughput Flow Cytometry for Discovery at UNMCMD and the NIH Molecular Libraries Initiative

High Throughput Flow Cytometry for Discovery at UNMCMD and the NIH Molecular Libraries Initiative By Dr Larry A. Sklar and Dr Bruce S. Edwards Commercial flow cytometers became widely established in research and clinical laboratories in the 1980s. Once the domain of immunologists and hematologists for cell sorting and analysis,… Read More

#Archive

#Academic #Analysis #Analytical chemistry #Animal models #Assay development optimisation & technology #Automation / robotics #Biochemistry #Biomarkers #Cell / tissue culture #Cell culture #Cell therapy #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Flow Cytometry #Gene therapy #Genetics / genomes #Genomics #High Content Screening #High throughput screening #Imaging #Immunology #Lead discovery #Mass spectrometry / NMR #Oncology #Pathology #Preclinical #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Stem cells #System biology #Systems biology #Target validation #Toxicology #Translational #Translational chemistry

Biomarkers Make Their Mark on Current Research and Drug Development Trends

Biomarkers Make Their Mark on Current Research and Drug Development Trends By Stephane Parent and Dr Gregory Cosentino Biomarkers continue to become increasingly relevant in research and healthcare applications, as evidenced by the global market for products involved in their identification, validation, and use estimated at $8.3 billion in 2007… Read More

#Archive

Electronic laboratory notebook (ELN)
#AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Automation / robotics #Biologics / Biotechnology #Business #Chemical engineering #Chemistry #Computational chemistry #Drug development #High Content Screening #Mass spectrometry / NMR #Pharmacology #Pharmokinetics #Preclinical #Regulatory #RNA #Sequencing #System biology #Systems biology #Target validation

Enterprise ELNs as a Foundation for Preclinical Drug Development

Enterprise ELNs as a Foundation for Preclinical Drug Development By Simon Beaulah, Dr Paul Denny- Gouldson and Dr Scott Weiss To have real business impact within preclinical drug development, Enterprise ELNs (Electronic Laboratory Notebooks) must provide a secure, scalable and searchable data management backbone across all disciplines focused on development… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Animal models #Assay development optimisation & technology #Automation / robotics #Biomarkers #Business #Cell / tissue culture #Cell culture #Cellular & Molecular biology #Cellular assays #Chemical engineering #Drug development #Drug discovery #Enabling technologies #Genetics / genomes #High Content Screening #High throughput screening #Imaging #Lead discovery #Microfluidics #Molecular medicine #Oncology #Pharmacology #Precision medicine #Protein chemistry / Proteomics #Regenerative Medicine #RNA #Screening #Stem cells #Toxicology

3D Cell Culture: Easier said than done

3D Cell Culture: Easier said than done By Dr John Comley The transition from cell culture on the flat surface of a conventional two-dimensional (2D) culture vessel to a three-dimensional (3D) environment, matrix or scaffold with 3D architecture has begun, and is providing much needed support for emerging applications in… Read More

#Archive